Outcomes for Bacterial Meningitis in Patients With Multiple Myeloma
Researchers sought to determine the outcomes for patients with multiple myeloma who develop bacterial meningitis.
Researchers sought to determine the outcomes for patients with multiple myeloma who develop bacterial meningitis.
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival.
Researchers sought to determine whether ocular toxicity occurred in a significant number of patients with multiple myeloma treated with belantamab mafodotin.
In stratified analysis, odds of all-cause mortality, hospital stay of more than five days higher for MM patients not using anticoagulation.
Researchers sought to determine the implications of plasma levels of microvesicles in patients with multiple myeloma.
Researchers sought to determine whether elevated CD24 expression on plasma cells was a prognostic factor in multiple myeloma.
An analysis of patient databases sought to determine which factors may contribute to poor adherence to oral anticancer agents among patients with MM.
Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
A single 150 mg dose of Evusheld demonstrated neutralizing activity against wild-type SARS-CoV-2 but not the omicron variant.
Researchers sought to determine whether patients were equally represented along designated racial groups in FDA drug trails for multiple myeloma.